Most of the failures are due to suboptimal adherence.
A growing number of HIV-infected patients in resource-constrained settings are now on second-line antiretroviral therapy (ART), but little is known about outcomes in such patients. To that end, researchers conducted a systematic review of 19 studies involving 2035 patients on second-line ART in Botswana, South Africa, Malawi, Uganda, Tanzania, Cambodia, Thailand, and rural China.
The cumulative pooled proportion of patients with virologic failure on second-line ART was 22% at 6 months, 27% at 24 months, and 38% at 36 months. Mortality rates after 12 months of second-line therapy ranged from 5% to 11%.
Only five studies assessed the potential role of adherence in second-line treatment failure, but they were consistent in showing that patients …
Reviewing Author
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes